Pharmaceutical Executive: December 2025 Volume 45 Issue 9 The GLP-1 Gold Rush Nicholas Jacobus Key Takeaways GLP-1 receptor agonists are reshaping chronic disease treatment, expanding beyond type 2 diabetes to obesity and other conditions, driving industry competition and innovation
Histologic evidence from massive weight loss demonstrates increased elastic fiber density compared to morbidly obese skin, but altered collagen architecture and decreased dermal thickness are common, which can translate to visible laxity even if elastic fibers are on the rise
The program is designed for convenience and fast access, helping patients begin treatment quickly while minimizing in-person barriers
Interested in screening and profiling inhibitors, blocking antibodies, or activators of GLP-1R without the need to purchase and license the cell line
When combined with semaglutidewhich also reduces blood sugar through insulin secretionthe risk of hypoglycemia (dangerously low blood sugar) increases, particularly in patients taking concurrent diabetes medications
Selective autophagy is programmed to degrade aggregates of proteins, invading pathogens, and damaged organelles, such as peroxisomes, mitochondria, lysosomes, nuclei, and endoplasmic reticula (ER) 54,55
